Benzinga's Top Pre-Market NASDAQ Gainers (CRXL, ALKS, CCME, RIMM)

Crucell NV CRXL rose 54.82% to $31.80 in the pre-market session. Johnson & Johnson JNJ has planned to acquire all the outstanding shares of CRXL for about 1.75 billion euros ($2.29 billion) or 24.75 euros per share, representing a 58% premium to CRXL's closing price of 15.70 euros on Thursday. Alkermes Inc ALKS added 6.89% to $15.20 in the pre-market session. FDA's Psychopharmacologic Drugs Advisory Committee has recommended approving ALKS' drug Vivitrol for opioid dependence treatment. China MediaExpress Holdings Inc CCME moved up 4.77% to $9.00 in the pre-market session. The Board of Directors of CCME had authorized a share buyback plan worth $30 million of its common stock. Research In Motion Limited RIMM soared 4.54% to $48.60 in the pre-market trading. RIMM had reported upbeat FQ2 results. Read more from Benzinga's Markets.